Acoramidis Beneficial in Transthyretin Amyloid Cardiomyopathy

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 11, 2024 -- Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients with transthyretin amyloid cardiomyopathy, according to a study published in the Jan. 11 issue of the New England Journal of Medicine.

Julian D. Gillmore, M.D., Ph.D., from University College London, and colleagues conducted a phase 3, double-blind trial involving 632 patients with transthyretin amyloid cardiomyopathy who were randomly assigned in a 2:1 ratio to receive acoramidis hydrochloride (800 mg twice daily) or matching placebo for 30 months. The primary hierarchical analysis included death from any cause, cardiovascular-related hospitalization, and the changes from baseline in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and 6-minute walk distance.

The researchers found that acoramidis was favored over placebo in the primary analysis, with a corresponding win ratio of 1.8, and 63.7 and 35.9 percent of pairwise comparisons favoring acoramidis and placebo, respectively. More than half the wins and losses to the win ratio were contributed by death from any cause and cardiovascular-related hospitalization together (58 percent of all pairwise comparisons); the highest ratio of wins to losses was yielded by NT-proBNP pairwise comparisons (23.3 versus 7.0 percent). The acoramidis and placebo groups had a similar overall incidence of adverse events (98.1 and 97.6 percent, respectively); serious adverse events occurred in 54.6 and 64.9 percent, respectively.

"These data support the use of acoramidis as an effective and safe treatment option for patients with transthyretin amyloid cardiomyopathy," the authors write.

The study was funded by BridgeBio Pharma, which is developing acoramidis.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-12 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords